Parallel to our study, Karlsson et al.41 also discovered that highly abundant CSF proteins, which are likely to be studied in the context of brain diseases, covary with the mean standardized CSF protein levels and further demonstrated that adjustment for this covariance using reference proteins increased the accuracy of established CSF biomarkers for amyloid and tau AD pathology. This evidence concerns the gene MAPT and amyloidosis.